NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Jeena Sikho Lifecare Limited (JSLL) has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 7, 2026, and concluded with the submission of the limited review report by statutory auditors. This announcement confirms the company's adherence to SEBI Listing Regulations 30 and 33. Investors should now focus on the detailed financial tables to assess the company's performance in the wellness and lifecare sector.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated results for the quarter ended December 31, 2025.Statutory Auditors issued a Limited Review Report for the nine-month period ending December 2025.The board meeting was conducted efficiently, starting at 04:05 P.M. and concluding at 04:35 P.M.Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should analyze the detailed financial statements for revenue growth and EBITDA margins once the full report is accessed. Monitor the stock for any price volatility following the earnings release.
JSLL Q3 FY26 Results: Revenue Up 92% YoY, PAT Surges 405% to ₹66.73 Crore
Jeena Sikho Lifecare Limited (JSLL) delivered exceptional Q3 FY26 performance, with revenue growing 92% YoY to ₹221.66 crore. Profitability saw a massive boost as PAT surged 405% YoY to ₹66.73 crore, supported by EBITDA margins expanding from 26% to 45%. The growth was driven by a 247% YoY increase in OPD patient volumes and an 84% rise in IPD volumes. The company is aggressively expanding with 475+ beds in the pipeline, bringing total capacity towards 2,800 beds.
முக்கிய அம்சங்கள்
Revenue from operations increased 92% YoY to ₹221.66 crore in Q3 FY26.PAT skyrocketed 405% YoY to ₹66.73 crore with PAT margins reaching 30%.EBITDA margins expanded significantly to 45% compared to 26% in Q3 FY25.OPD, COD, and Video-Call patient volumes grew 247% YoY to 4.34 lakhs.Current operational capacity is 2,290 beds with 475+ additional beds under development.
👀 கவனிக்க வேண்டியவை
Investors should view the massive margin expansion and volume growth as a sign of high operational leverage and scalability. The company's transition to the mainboard and its aggressive bed expansion pipeline make it a strong growth candidate in the Ayurvedic healthcare sector.
Jeena Sikho Lifecare Limited (JSLL) has announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved both standalone and consolidated unaudited results during their meeting on February 7, 2026. The filing includes the Limited Review Report from statutory auditors, ensuring regulatory compliance under SEBI guidelines. Investors should now focus on the detailed financial statements to evaluate the company's growth and margin performance in the healthcare sector.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025.Statutory auditors provided a Limited Review Report for the nine-month period ending December 2025.The board meeting was conducted and concluded within a 30-minute window (04:05 P.M. to 04:35 P.M.).Compliance maintained as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should scrutinize the detailed profit and loss statements and balance sheet figures to assess the company's operational efficiency. Compare the Q3 results with previous quarters to identify any seasonal trends or growth momentum in the lifecare business.
Jeena Sikho Lifecare Commences Operations at Two New Hospitals in Siliguri and Bhagalpur
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at two new hospital facilities in Siliguri, West Bengal, and Bhagalpur, Bihar, effective February 3, 2026. The Siliguri facility adds 35 beds and 29 rooms, while the Bhagalpur unit adds 25 beds and 18 rooms to the company's healthcare network. Both facilities occupy 10,000 sq. ft. each and include dedicated OPD services. This expansion follows through on proposals initiated in 2025, demonstrating the company's commitment to scaling its physical infrastructure in the Eastern region.
முக்கிய அம்சங்கள்
Commenced operations at two new hospitals in West Bengal and Bihar on February 3, 2026Siliguri facility features 35 beds, 29 rooms, and 3 OPDs across 10,000 sq. ft.Bhagalpur facility features 25 beds, 18 rooms, and 2 OPDs across 10,000 sq. ft.Total capacity addition of 60 beds and 47 rooms across the two new locationsExecution of expansion plans within approximately one year of initial proposal
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational milestone that will likely contribute to revenue growth in the coming quarters. Monitor the occupancy rates and the company's ability to scale these new centers profitably.
JSLL to Engage with 25+ Institutional Investors at Nuvama 21st India Conference
Jeena Sikho Lifecare Limited (JSLL) has scheduled a series of group meetings with over 25 prominent institutional investors and asset management companies on February 10, 2026. The meetings will take place during the Nuvama 21st India Conference at Hotel Grand Hyatt, Mumbai. Participating entities include high-profile names such as PPFAS Mutual Fund, Motilal Oswal AMC, UTI Mutual Fund, and Aditya Birla Sun Life. These interactions are intended to discuss the company's business based on publicly available information, potentially increasing institutional visibility.
முக்கிய அம்சங்கள்
Scheduled meetings with 25+ institutional investors and mutual funds on February 10, 2026.Participation from top-tier funds including PPFAS Mutual Fund, Motilal Oswal AMC, and UTI Mutual Fund.Four distinct group meeting slots scheduled between 10:00 AM and 1:50 PM.Interaction organized as part of the Nuvama 21st India Conference in Mumbai.
👀 கவனிக்க வேண்டியவை
Investors should monitor for any post-conference analyst reports or increased institutional buying activity. The high level of interest from reputed funds suggests growing institutional confidence in the company's business model.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Jindal Stainless Q3 FY26: PAT Rises 27% YoY to ₹828 Cr; Sales Volume Up 11%
Jindal Stainless Limited (JSL) reported a strong Q3 FY26 with consolidated PAT growing 27% YoY to ₹828 crores and sales volumes increasing 11% to 0.65 million tonnes. The company maintained steady domestic demand across automotive, railways, and white goods sectors, despite global export headwinds and import pressures. Financial health remains robust with net debt reducing to ₹3,451 crores and a healthy net debt-to-EBITDA ratio of 0.67. Management reaffirmed its EBITDA per tonne guidance of ₹19,000-₹21,000, having achieved ₹21,300 in the first nine months of the fiscal year.
முக்கிய அம்சங்கள்
Consolidated EBITDA grew 17% YoY to ₹1,408 crores with a 9M average EBITDA per ton of ₹21,300.Sales volume reached 0.65 million tonnes in Q3, marking an 11% YoY growth driven by domestic demand.Net debt significantly reduced to ₹3,451 crores, resulting in a low net debt-to-equity ratio of 0.18.Board approved an interim dividend of ₹1 per share (50% of face value) for FY26 with a record date of Jan 29, 2026.Renewable power utilization increased to 56% of total imported power at Jajpur and Hisar facilities.
👀 கவனிக்க வேண்டியவை
Investors should view the steady volume growth and significant debt reduction as positive indicators of operational efficiency and financial discipline. Monitor the government's upcoming decisions on anti-dumping duties and QCO enforcement as they will be critical for long-term margin protection against imports.
JSLL Reports One-Year Disease-Free Cancer Care Success in Peer-Reviewed Ayush Journal
Jeena Sikho Lifecare Limited (JSLL) has published a clinical case report in the 'Ayush Journal of Integrative Oncology' documenting a successful outcome for a 53-year-old breast cancer survivor. The report highlights a one-year disease-free resolution of recurrent lymphadenopathy achieved through the company's proprietary Ayurvedic protocols and lifestyle modifications. Co-authored by the Managing Director and the R&D team, this publication provides evidence-based validation for JSLL's clinical practices. This move is intended to strengthen the company's credibility in the integrative oncology space and support its research-driven growth strategy.
முக்கிய அம்சங்கள்
Published case report in 'Ayush Journal of Integrative Oncology' documents a one-year disease-free status for a post-mastectomy patient.Clinical resolution was documented via PET-CT scans, providing objective evidence for the efficacy of the Ayurvedic interventions.The publication was co-authored by Managing Director Acharya Manish Grover and JSLL's Department of Research and Development.Treatment involved a combination of personalized Ayurvedic formulations, Panchakarma therapies, and a 'Circadian D.I.P. diet'.The report reflects the company's commitment to advancing Ayurvedic research and evidence-based clinical practices.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward clinical validation of the company's treatments, which enhances brand trust and market positioning. Monitor for further R&D milestones that could drive long-term patient acquisition and revenue growth.
JSLL Approves AED 7.53 Million Unsecured Loan to International Subsidiary
Jeena Sikho Lifecare Limited (JSLL) has approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC. The loan, to be disbursed in two tranches, carries an interest rate of 8.5% per annum with a tenure of five years to support the subsidiary's operational requirements. Separately, the company disclosed it has paid fines imposed by the NSE and BSE for past non-compliance with SEBI Regulation 29. This capital infusion suggests a focus on international expansion while the company works to strengthen its internal compliance systems.
முக்கிய அம்சங்கள்
Approved an unsecured loan of AED 7.53 million to wholly-owned subsidiary Jeena Sikho International LLCLoan features an interest rate of 8.5% per annum on a simple interest basisThe loan tenure is set for 5 years from the date of the first disbursementPaid fines to NSE and BSE for non-compliance with Regulation 29 regarding board meeting intimationsTransaction is confirmed to be on an arm's length basis as a related party transaction
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth and revenue contribution of the international subsidiary following this capital infusion. Additionally, keep a watch on the company's future regulatory filings to ensure compliance issues are fully resolved.
Jindal Stainless Q3 FY26 PAT Jumps 27% YoY to ₹828 Cr; Sales Volume Up 11%
Jindal Stainless Limited (JSL) reported a strong financial performance for Q3 FY26, with consolidated PAT rising 27% YoY to ₹828 crore. Revenue grew 6% YoY to ₹10,518 crore, driven by an 11% increase in sales volumes to 650,000 MT. The company demonstrated significant deleveraging, reducing net debt to ₹3,451 crore from ₹3,991 crore in March 2025, resulting in a healthy Net Debt/EBITDA ratio of 0.67. Management maintains a positive outlook for Q4 FY26, citing strong demand in the railway, infrastructure, and automobile sectors, further supported by recent GST rate cuts.
முக்கிய அம்சங்கள்
Consolidated PAT increased 27% YoY to ₹828 crore in Q3 FY26.Sales volume grew 11% YoY to 650,000 MT, with domestic markets contributing 95% of Q3 volume.Consolidated EBITDA rose 17% YoY to ₹1,408 crore, reflecting improved operational efficiency.Net debt reduced by ₹540 crore over nine months to ₹3,451 crore as of December 2025.Strong demand outlook in Railways driven by Vande Bharat sleeper trainsets and Metro projects.
👀 கவனிக்க வேண்டியவை
Investors should view the strong volume growth and consistent debt reduction as positive indicators of JSL's market leadership and financial health. The stock remains a key beneficiary of India's infrastructure push and the shift toward stainless steel in railways and automobiles.
Jindal Stainless Sets Jan 29 as Record Date for INR 1 Interim Dividend
Jindal Stainless Limited (JSL) has announced January 29, 2026, as the record date for its interim dividend for the financial year 2025-26. The company will pay a dividend of INR 1 per equity share, which has a face value of INR 2. Shareholders whose names appear in the register as of the record date will be eligible for the payout. The payment process is scheduled to be completed on or before February 19, 2026.
முக்கிய அம்சங்கள்
Interim dividend of INR 1 per equity share declared for FY 2025-26Record date for determining eligibility is fixed as January 29, 2026Dividend payment to be completed by February 19, 2026Face value of the equity shares stands at INR 2 each
👀 கவனிக்க வேண்டியவை
Investors seeking to qualify for the dividend should ensure they purchase or hold the stock before the ex-dividend date. This payout reflects the company's commitment to sharing profits with its shareholders.
JSL Q3 PAT Rises 7.6% YoY to ₹666 Cr; Announces ₹1 Interim Dividend
Jindal Stainless Limited (JSL) reported a steady Q3 FY26 performance with standalone Profit After Tax (PAT) reaching ₹665.85 crore, a 7.6% increase year-on-year. While revenue saw a slight sequential dip to ₹10,632 crore, operating margins improved to 10.38% from 9.74% in the preceding quarter. The board has declared an interim dividend of ₹1 per share (50% of face value) with a record date of January 29, 2026. Furthermore, the company continues to deleverage, with its debt-to-equity ratio improving to 0.24.
முக்கிய அம்சங்கள்
Standalone Net Profit increased to ₹665.85 crore in Q3 FY26 from ₹618.64 crore in Q3 FY25.Operating margin expanded to 10.38% in the current quarter compared to 9.74% in Q2 FY26.Declared an interim dividend of ₹1 per equity share (50% of face value) for FY 2025-26.Debt-to-equity ratio improved significantly to 0.24 from 0.33 in the year-ago period.Re-appointed three Independent Directors, including Dr. Aarti Gupta, for a second three-year term.
👀 கவனிக்க வேண்டியவை
Investors should take note of the improving operating margins and consistent debt reduction, which strengthen the company's financial profile. The stock remains a healthy pick for long-term exposure to the stainless steel sector, supported by regular dividend payouts.
Jindal Stainless Q3FY26 PAT Rises 26.6% to ₹828 Cr; Declares ₹1 Interim Dividend
Jindal Stainless Limited (JSL) reported a robust Q3 FY26 with consolidated PAT growing 26.6% Y-o-Y to INR 828 crore, driven by a 10.6% increase in sales volumes. Despite global export headwinds and a surge in low-priced imports from China and ASEAN, the company maintained its market share by focusing on the domestic market, which now accounts for 94.6% of total sales. Financial health remains strong with a low net debt-to-equity ratio of 0.18x and a consolidated EBITDA growth of 16.6%. The board also declared an interim dividend of INR 1 per share (50% of face value).
முக்கிய அம்சங்கள்
Consolidated PAT surged 26.6% Y-o-Y to INR 828 crore, while EBITDA rose 16.6% to INR 1,408 crore.Sales volume grew by 10.6% Y-o-Y to 6,49,857 tonnes, supported by demand from automotive and infrastructure sectors.Net debt stands at a healthy INR 3,451 crore with a very low net debt-to-equity ratio of 0.18x.Domestic sales mix increased to 94.6% as the company strategically pivoted away from subdued export markets.Declared an interim dividend of INR 1 per share with a record date of January 29, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the strong volume growth and margin expansion positively, especially given the challenging import environment. The company's low leverage and strategic entry into high-value segments like defense provide long-term growth visibility.
Jeena Sikho Lifecare to Acquire 51% Stake in UAE-based Back to Roots Ayurveda for AED 1.53 Million
Jeena Sikho Lifecare Limited (JSLL) has announced that its international subsidiary will acquire a 51% controlling stake in Abu Dhabi-based Back to Roots Ayurveda for AED 1.53 million. This acquisition marks a significant step in JSLL's global expansion strategy within the Ayurveda and wellness sector. The target entity has shown rapid growth, with turnover increasing from AED 0.77 million in 2024 to AED 2.5 million in 2025. The transaction is expected to be completed within 2-3 months via cash consideration, making it a step-down subsidiary of JSLL.
முக்கிய அம்சங்கள்
Acquisition of 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC for AED 1.53 million.Target company turnover grew over 220% year-on-year, reaching AED 2.5 million in 2025 from AED 0.77 million in 2024.The deal establishes a strategic international footprint for JSLL in the UAE's growing wellness and Panchakarma market.The acquisition is a cash-only transaction expected to be finalized within approximately 2-3 months.Back to Roots Ayurveda is a relatively new entity, incorporated in December 2023, showing high growth potential.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this international expansion as it diversifies revenue streams into a high-margin wellness market. Monitor the successful integration of the UAE operations and its impact on consolidated profitability in the next fiscal year.
Jeena Sikho Lifecare Partners with Theryco for Amazon E-commerce Distribution
Jeena Sikho Lifecare Limited (JSLL) has entered into a procurement agreement with Theryco Healthcare Solutions Private Limited to enhance its digital presence. Under this agreement, dated January 3, 2026, Theryco is authorized to list, manage, and sell JSLL's products on the Amazon e-commerce platform. This strategic move is intended to strengthen the company's distribution reach and improve product availability across digital channels. The company has confirmed that the transaction is on an arm's length basis and does not involve any related parties.
முக்கிய அம்சங்கள்
Procurement agreement signed with Theryco Healthcare Solutions on January 3, 2026.Theryco authorized to manage and sell JSLL products specifically on the Amazon platform.Strategic focus on strengthening digital distribution and enhancing product availability.Transaction confirmed as non-related party and executed on an arm's length basis.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming quarterly results to see if this digital expansion translates into higher sales volumes. This move indicates a positive shift towards modernizing distribution channels.
JSLL Publishes Research on Ayurvedic Diabetes Care; HbA1c Drops from 7.3% to 6.4%
Jeena Sikho Lifecare Limited (JSLL) has published two research articles in international journals validating its Ayurvedic treatment protocols for Type 2 Diabetes and Chronic Kidney Disease. A key case study highlighted a patient's HbA1c reduction from 7.3% to 6.4% and a significant recovery in pancreatic function, with fecal elastase increasing from 102 µg/g to 694 µg/g. The study also reported a 50% reduction in triglycerides, from 439 mg/dl to 220 mg/dl, and a decrease in total cholesterol from 217 mg/dl to 157 mg/dl. These publications support the company's commitment to evidence-based Ayurveda and clinical advancement.
முக்கிய அம்சங்கள்
Published two research papers in the European Journal of Pharmaceutical and Medical Research and IJARPatient HbA1c levels decreased from 7.3% to 6.4% following Ayurvedic interventionFecal pancreatic elastase levels improved significantly from 102 µg/g to 694 µg/gTriglycerides were reduced by 50%, falling from 439 mg/dl to 220 mg/dlResearch authored by JSLL's Managing Director and senior medical consultants
👀 கவனிக்க வேண்டியவை
This scientific validation enhances the company's clinical credibility and brand value in the competitive wellness sector. Long-term investors should monitor if such research leads to higher patient acquisition and revenue growth.
Jindal Stainless Receives ESG Rating of 71 for FY 2024-25 from NSE Sustainability
Jindal Stainless Limited (JSL) has been assigned an ESG rating of 71 for the Financial Year 2024-25 by NSE Sustainability Ratings & Analytics. This rating is a result of the company's compliance with the updated SEBI guidelines for ESG disclosures by registered providers. A score of 71 reflects the company's commitment to environmental, social, and governance standards in the manufacturing sector. This standardized rating allows institutional investors to better assess the company's non-financial risk profile and sustainability performance.
முக்கிய அம்சங்கள்
NSE Sustainability Ratings & Analytics assigned an ESG rating of 71 to the company.The rating is specifically for the Financial Year 2024-25 performance.The disclosure follows the SEBI circular dated November 11, 2024, regarding ESG Rating Providers.JSL is among the major steel players to report standardized ESG scores under the new regulatory framework.
👀 கவனிக்க வேண்டியவை
Investors should consider this rating as a positive sign of transparency and ESG compliance, which may attract ESG-focused institutional funds. Monitor how this score compares to industry peers to gauge JSL's relative sustainability leadership.
India Ratings Upgrades Jindal Stainless Outlook to Positive; Affirms IND AA Rating
India Ratings & Research has revised the credit rating outlook for Jindal Stainless Limited's long-term borrowings from 'Stable' to 'Positive' while affirming the rating at 'IND AA'. The agency also reaffirmed the company's short-term borrowing rating at 'IND A1+', which is the highest possible rating for short-term instruments. This outlook revision indicates a strengthening financial profile and the potential for a formal rating upgrade in the near future. Such improvements typically lead to lower interest costs and enhanced access to capital markets.
முக்கிய அம்சங்கள்
Long-term borrowing outlook upgraded from 'IND AA, Stable' to 'IND AA, Positive'.Short-term borrowing rating affirmed at 'IND A1+', the highest credit quality for short-term debt.The revision by India Ratings & Research reflects improved credit metrics and operational stability.A positive outlook suggests a high likelihood of a rating upgrade to AA+ within the next 12-18 months.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong signal of the company's improving balance sheet and reduced financial risk. The potential for lower borrowing costs in the future could provide a boost to net profit margins.
JSLL Sanganer Hospital Receives NABH Accreditation for Panchakarma Services
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certificate for its Sanganer Hospital in Rajasthan. The accreditation specifically covers Panchakarma services and is valid under certification number AH-2025-0412 until November 10, 2028. This certification validates the company's commitment to high standards of patient safety and quality healthcare delivery. Such accreditations are vital for healthcare providers to enhance brand reputation and facilitate empanelment with insurance providers.
முக்கிய அம்சங்கள்
Received NABH Certificate of Accreditation for Sanganer Hospital located in Rajasthan.The accreditation is specifically for Panchakarma services under certification number AH-2025-0412.The certificate is valid for a multi-year period expiring on November 10, 2028.Signifies adherence to nationally recognized standards for quality healthcare and operational excellence.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational milestone that strengthens the company's competitive position in the Ayurvedic healthcare sector. Monitor for potential improvements in patient footfall and insurance tie-ups following this accreditation.
Jeena Sikho Lifecare Publishes Research on Ayurvedic CKD Treatment; Creatinine Levels Drop to 5.17
Jeena Sikho Lifecare Limited (JSLL) has announced the publication of three academic case studies and reports in international journals focusing on Ayurvedic management of Chronic Kidney Disease (CKD). A key case study highlighted in the filing demonstrated significant clinical improvements in a 56-year-old patient, with serum urea dropping from 230.86 mg/dL to 117.39 mg/dL and creatinine reducing from 6.32 mg/dL to 5.17 mg/dL. The research validates the company's proprietary Ayurvedic formulations and specialized 'DIP' diet protocols. These publications are part of JSLL's strategy to establish evidence-based credibility for its clinical practices and hospital-based treatments.
முக்கிய அம்சங்கள்
Published three academic papers in the International Journal of Ayurveda and Herbal Research and Journal of Applied Science and Education.Clinical results showed a significant serum urea reduction of approximately 49% (from 230.86 mg/dL to 117.39 mg/dL).Serum creatinine levels improved from 6.32 mg/dL to 5.17 mg/dL during the observed treatment period.Fasting blood sugar levels normalized from 130 mg/dL to 90 mg/dL, indicating improved metabolic control.Research was co-authored by Managing Director Manish Grover and a team of senior Ayurvedic consultants and medical professionals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward clinical validation of the company's Ayurvedic protocols, which could enhance brand trust and patient footfall. Monitor if this scientific validation leads to increased revenue in the hospital and wellness product segments.
Jindal Stainless Receives ESG Rating of 68.3 for FY 2024-25
Jindal Stainless Limited (JSL) has announced its ESG rating for the Financial Year 2024-25 as per SEBI's updated disclosure requirements. The company was assigned a score of 68.3 by SES ESG Research Private Limited, a SEBI-registered Category II ESG Rating Provider. This disclosure follows the SEBI circular dated November 11, 2024, emphasizing standardized ESG reporting for listed entities. The rating provides a benchmark for the company's sustainability and governance performance relative to its peers.
முக்கிய அம்சங்கள்
Assigned an ESG rating of 68.3 for the Financial Year 2024-25Rating conducted by SES ESG Research Private Limited, a subsidiary of Stakeholders Empowerment ServicesCompliance with SEBI Circular SEBI/HO/CFD/CFD-PoD2/CIR/P/0155 regarding ESG disclosuresThe rating provider is a SEBI-registered Category II ESG Rating Provider
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward transparency and institutional compliance, which may attract ESG-focused funds. Compare this score of 68.3 with other steel sector peers to evaluate JSL's relative sustainability standing.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
